How can a nomogram model using my age and ultrasound features help distinguish my papillary thyroid carcinoma from benign nodules?

A nomogram is a simple visual tool that doctors use to estimate risk. For thyroid nodules, a nomogram can combine your age, ultrasound features (such as nodule size, shape, and presence of microcalcifications), and sometimes blood test results to give a personalized probability that a nodule is papillary thyroid carcinoma (PTC) rather than benign. This helps guide decisions about whether to do a biopsy or surgery. One study developed a nomogram that included age, ultrasound features, and a blood marker called NLR (neutrophil-to-lymphocyte ratio) and found it accurately distinguished PTC from benign nodules, with an AUC (a measure of accuracy) of 0.841 in the training group ³. Another nomogram used age, ultrasound-reported lymph node status, and an ultrasound signature based on tumor size and microcalcifications to predict central lymph node metastasis in PTC ¹⁰. These models are not perfect, but they provide a more precise risk estimate than ultrasound alone.

What the research says

A 2024 study created a nomogram that combined patient age, ultrasound features, and the neutrophil-to-lymphocyte ratio (NLR) to tell PTC apart from benign thyroid nodules ³. The model was tested on over 1,000 patients from multiple hospitals and showed good accuracy, with AUC values ranging from 0.756 to 0.841 across different groups ³. This means the model correctly identified PTC versus benign nodules about 76% to 84% of the time, depending on the group ³. The study also confirmed the model's clinical usefulness through decision curve analysis ³.

Another nomogram, published in 2020, focused on predicting central lymph node metastasis (cancer spread to lymph nodes in the neck) in PTC patients ¹⁰. This model used age, an ultrasound signature (based on tumor size and microcalcifications), and ultrasound-reported lymph node status ¹⁰. It performed well in male and young female patients, with AUCs around 0.81 to 0.83, but was less accurate in older women ¹⁰. This shows that age and sex can affect how well these models work.

Other research has looked at different factors that might improve prediction. For example, a machine learning model for predicting lymph node metastasis in early-stage PTC found that age ≤55 years, tumor size >1.0 cm, and certain blood markers were important predictors ¹. While not a nomogram, this supports the idea that combining age and ultrasound features with other data can improve risk assessment. Similarly, BRAFV600E mutation testing has been shown to strongly predict PTC in high-suspicion nodules, with an odds ratio of 10.36 ⁵. However, this requires a biopsy sample, whereas a nomogram using only age and ultrasound is non-invasive.

It is important to note that no single model is 100% accurate. The nomogram from the 2024 study had an AUC of 0.841 in the training set, meaning about 84% of the time it correctly distinguished PTC from benign nodules ³. This is good, but still leaves room for error. Doctors typically use nomograms as one piece of information alongside other tests like fine-needle aspiration biopsy.

What to ask your doctor

• Based on my age and ultrasound results, what is my estimated risk that this nodule is cancerous according to available nomogram models?
• Would adding a blood test like NLR (neutrophil-to-lymphocyte ratio) improve the accuracy of my risk assessment?
• How does the nomogram's prediction compare to the results of my fine-needle aspiration biopsy (if I had one)?
• If the nomogram suggests a high risk, what are the next steps — repeat ultrasound, biopsy, or surgery?
• Are there any other factors, such as family history or nodule size, that might change my risk estimate beyond what the nomogram shows?